What kind of research is supported through the CCS?
The CCS offers programs to support a broad spectrum of leading-edge research into all types of cancer, from basic laboratory research to clinical trials to behavioural studies. Funded areas include, but are not limited to:
- biological studies (biochemistry, genetics, immunology and molecular biology of cancer)
- chemical studies (carcinogenesis, medicinal chemistry, experimental therapeutics, drug development and drug delivery)
- physical sciences (biophysics imaging, radiobiology and photobiology)
- clinical sciences (chemotherapy, pathology, psychology and psychosocial studies)
- population health sciences (community health, health promotion, health services, epidemiology and occupational/ environmental health sciences, health economics)
- translational research (rapidly moving research results into better treatments, prevention, and risk reduction strategies)
- cancer prevention, early detection, screening, diagnosis, treatment, rehabilitation, related psychosocial issues, complementary and alternative medicine
- knowledge mobilization, such as the development and testing of programs and interventions based on research evidence
- research which could lead to improvements in the quality of life of people with cancer, for example by improving the effectiveness of treatments or addressing symptom control
What are the eligibility requirements for a research grant?
Applicants must be based in, or formally affiliated with, an eligible Canadian Host Institution such as a university, research institute or health care agency. Only investigators meeting this criteria can apply for funds. Investigators who do not meet these requirements may be collaborators on funded Canadian Cancer Society research projects but can’t receive funding themselves.
How do I apply for funding?
The Canadian Cancer Society offers grant competitions in a variety of program areas. Each of these requires a formal application and is subject to specific eligibility and other requirements. All applications are submitted online through our EGrAMS
system, which provides guidance throughout the application process.
How will I know if my application is successful?
Successful applications will be listed on the website alphabetically by the principal investigator’s surname for each competition and will receive official notification directly. Co-principal investigators, co-applicants and additional authors do not appear on the website. Successful applicants will also be contacted by Canadian Cancer Society. Once results are announced, applicants will be able to access panel reviews via EGrAMS
When can I apply for funding?
Each program has a specific deadline. Details on these competitions can be found under the program links here.
Are letters of intent or abstract registration required for all competitions?
A letter of intent is required for our Impact Grants, Prevention Research Grants and the Quality of Life Research Grants; abstract registration is required for our Innovation Grants, Innovation to Impact Grants and Knowledge to Action Grants. For more detail, please see the program pages.
Who serves on the Canadian Cancer Society research peer review panels?
Review panels consist of a chair, members, and scientific officers who are all highly respected cancer researchers, and community representatives who comment on the potential impact of the proposed work from a lay perspective – often cancer survivors themselves – who are endorsed by the Canadian Cancer Society or possibly another Canadian cancer organization. We operate many different panels to evaluate a wide range of cancer research proposals. You can view a list of our current panel memberships here
What is the success rate for grant applications?
Funding statistics for recent competitions are available on our website here
Can I apply for a research position with the Canadian Cancer Society?
No. The CCS is a research funder, it does not conduct independent research.
To apply for funding, please go to our EGrAMS
grant management system.
Last modified on: October 20, 2017